Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
N/A
Address
Description
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.28
Trade Value (12mth)
AU$7,488.00
1 week
5.88%
1 month
20%
YTD
9.09%
1 year
190.32%
All time high
0.62
EPS 3 yr Growth
29.90%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-192.20%
ROIC
-173.40%
Interest Coverage
-89.30
Quick Ratio
2.50
Shares on Issue (Fully Dilluted)
143m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
08 May 25 |
Investor Presentation
×
Investor Presentation |
30 April 25 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
23 April 25 |
Phase 2a/b clinical trial update
×
Phase 2a/b clinical trial update |
14 April 25 |
Notification of cessation of securities - ILA
×
Notification of cessation of securities - ILA |
26 March 25 |
Change in substantial holding
×
Change in substantial holding |
25 March 25 |
Change in substantial holding
×
Change in substantial holding |
25 March 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
24 March 25 |
Spark Plus Healthcare Conference Investor Presentation
×
Spark Plus Healthcare Conference Investor Presentation |
24 March 25 |
Change in substantial holding
×
Change in substantial holding |
21 March 25 |
Change in substantial holding
×
Change in substantial holding |
19 March 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
19 March 25 |
Change of Director's Interest Notice - PL
×
Change of Director's Interest Notice - PL |
19 March 25 |
Notification of cessation of securities - ILA
×
Notification of cessation of securities - ILA |
19 March 25 |
Total of $2.72m raised from ILAO options
×
Total of $2.72m raised from ILAO options |
12 March 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
05 March 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
05 March 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
05 March 25 |
Cleansing Notice
×
Cleansing Notice |
05 March 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
05 March 25 |
Change of Director's Interest Notice - DF
×
Change of Director's Interest Notice - DF |
27 February 25 |
Appendix 4D & Half-Year Financial Statements
×
Appendix 4D & Half-Year Financial Statements |
26 February 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
19 February 25 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
19 February 25 |
Change in substantial holding
×
Change in substantial holding |
13 February 25 |
Change of Director's Interest Notice (PL)
×
Change of Director's Interest Notice (PL) |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.